Van Herk Ventures

Van Herk Ventures operates as the dedicated life sciences investment arm of the Van Herk Groep, a private investment company based in Rotterdam, The Netherlands. Established by Mr. A. van Herk, the broader group maintains diverse interests spanning real estate and financial investments, but its life sciences division is a highly active and strategic player. Van Herk Ventures primarily focuses on innovative biotech and medtech companies, demonstrating a strong commitment to advancing medical science and technology. Their investment philosophy emphasizes a long-term partnership approach, often supporting companies through multiple funding rounds.

The firm's investment scope is notably broad, ranging from early-stage seed funding to substantial growth capital. This flexibility allows Van Herk Ventures to engage with promising ventures at various points in their development, from nascent concepts requiring initial capital to mature companies seeking significant expansion funds. They invest in both privately held and publicly listed entities, reflecting a comprehensive strategy to capitalize on opportunities across the life sciences spectrum. This versatile approach positions them as a key financial and strategic partner for companies aiming for significant milestones.

Van Herk Ventures boasts a robust portfolio of successful investments, underscoring their expertise and impact in the sector. A notable success story includes their early and significant backing of Acerta Pharma, which was subsequently acquired by AstraZeneca in a deal valued at up to $7 billion. This acquisition highlights Van Herk Ventures' capacity to identify and nurture companies that achieve substantial exits. Furthermore, their participation in growth rounds, such as the €25 million Series B funding for Azafaros in 2021, illustrates their commitment to providing substantial capital for companies poised for significant development.

The firm's strategic location in the Netherlands, a burgeoning hub for life sciences innovation, provides them with access to a rich ecosystem of talent and research. By combining deep industry knowledge with flexible capital deployment, Van Herk Ventures continues to be a pivotal investor, contributing significantly to the growth and commercialization of groundbreaking life sciences technologies. Their patient capital and hands-on approach make them a preferred partner for entrepreneurs in the biotech and medtech fields.